EP Patent

EP3986416A1 — Methods of treating congenital adrenal hyperplasia

Assigned to Spruce Biosciences Inc · Expires 2022-04-27 · 4y expired

What this patent protects

Patients with congenital adrenal hyperplasia (CAH) need adequate care and treatment in order to lead normal lives. Hence, there is a need for new methods of treating CAH. This disclosure provides new compounds, salts, compositions and uses thereof in the treatment of CAH.

USPTO Abstract

Patients with congenital adrenal hyperplasia (CAH) need adequate care and treatment in order to lead normal lives. Hence, there is a need for new methods of treating CAH. This disclosure provides new compounds, salts, compositions and uses thereof in the treatment of CAH.

Drugs covered by this patent

Patent Metadata

Patent number
EP3986416A1
Jurisdiction
EP
Classification
—
Expires
2022-04-27
Drug substance claim
No
Drug product claim
No
Assignee
Spruce Biosciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.